Holen Sie sich die Stockscreener-App
199.59
1.22%
2.40
Vorhandelsmarkt:
199.59
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation - simplywall.st
Enterprise value to EBITDA forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Price to book forward of Biogen Inc. – TURQUOISE:BIIBN - TradingView
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Expands Spinraza Patent Fight With Cipla, Somerset Suits - Bloomberg Law News
Biogen updates Alzheimer’s pipeline plans, shares on Nasdaq in focus - Ad-hoc-news.de
Biogen to Acquire RayThera for Up to $1 Billion - Global Legal Chronicle
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - GlobeNewswire Inc.
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Omada Health, Inc. (OMDA) - The Globe and Mail
WilmerHale Advises Biogen in Acquisition of RayThera - WilmerHale
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook - Investing.com
Biogen to acquire RayThera for USD 1B - Medical Buyer
Biogen Inc. (BIIB) Investor Outlook: Evaluating the Potential 12% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biogen Inc. (BIIB) And Encourages Shareholders to Reach Out - ACCESS Newswire
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Biogen acquires RayThera in deal worth up to $1 billion - qz.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Biogen Stock$1 billion RayThera deal to expand immunology pipeline - AD HOC NEWS
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera - BioPharma Dive
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Benzinga
Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. - Pharmaceutical Executive
Biogen snags San Diego biotech for $1B as immunology expansion continues - The Business Journals
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout - Yahoo Finance
Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says - marketscreener.com
Biogen Agrees to Acquire RayThera for Up to $1B - Contract Pharma
Needham reiterates Buy on Biogen stock after RayThera acquisition - Investing.com
Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com - Investing.com Canada
Biogen makes up to $1B immuno play with RayThera takeover - BioSpace
Biogen (BIIB) Expands Immunology Portfolio with $1B RayThera Acquisition - Blockonomi
Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline - marketscreener.com
Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating - marketscreener.com
Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus
Biogen to Acquire Biotechnology Firm RayThera for Up to $1 Billion - marketscreener.com
Biogen Inc (BIIB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biogen (BIIB) to Acquire RayThera for Up to $1 Billion - GuruFocus
Biogen targets immunology growth with $1 billion RayThera deal - Reuters
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Biogen to acquire RayThera for up to $1 billion - Investing.com
Biogen to acquire RayThera for up to $1B, boosting immunology pipeline with new drug candidates. - Pluang
Biogen to Acquire RayThera for Up to $1 Billion to Expand Immunology Pipeline - Quiver Quantitative
Biogen to acquire RayThera for up to $1 billion By Investing.com - Investing.com Canada
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. - Biogen
Biogen to acquire RayThera for $1 billion - marketscreener.com
Biogen Expands Immunology Pipeline With Agreement To Acquire Raythera Inc. - TradingView
Biogen Expands Immunology Pipeline with $1 Billion RayThera Acquisition to Advance Next-Generation Therapies - bio-itworld.com
Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion. - marketscreener.com
Biogen to Report Second Quarter 2026 Financial Results July 29, 2026 - Biogen
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for SKYCLARYS™ - Yahoo Finance
Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story - simplywall.st
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
2026-06-15 | Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse
Mizuho Trims Price Target on Biogen to $221 From $236, Keeps Outperform Rating - marketscreener.com
2.75%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):